Phase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 3 Trial: Ifinatamab Deruxtecan (MK-2400) for metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: HSK46575 a Novel CYP11A1 Inhibitor for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Trial: Targeting Resistance With SX-682 And Apalutamide or Enzalutamide
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial for DR-0202 Bispecific Antibody for Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: PMR-116, Targeting The Undruggable MYC Oncogene
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent
/in Clinical Trial, Metastatic, Phase 1/by MaxSn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use April 25, 2026
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026